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In Reply Latent tuberculous infection testing among HIV-infected 
persons in clinical care
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Tuberculosis (TB) is the leading preventable cause of death among persons living with the 
human immunodeficiency virus (PLHIV) worldwide. The current US guidelines for the 
prevention of opportunistic infections in HIV-infected adults and adolescents recommend 
testing for latent tuberculous infection (LTBI) at the time of HIV diagnosis, regardless of 
other TB risk factors, and annually thereafter in PLHIV with initial negative LTBI testing 
results who are at continued high risk of exposure to Mycobacterium tuberculosis.1 
Evaluation of PLHIV for TB disease and infection reduces morbidity and mortality, and 
prevents future TB transmission.2,3 However, we published a study in this Journal that 
evaluated a nationally representative sample of 2772 PLHIV in care in the United States 
during 2010–2012, and found that more than 30% of PLHIV diagnosed with HIV infection 
in the previous 5 years had no documentation of ever being tested for LTBI.4
While testing for LTBI among PLHIV in the Netherlands is not routine, the study by van 
Bentum et al. observed positive LTBI test results among 4.8% of their study population, 
highlighting the critical importance of screening PLHIV.5
Evidence supporting annual TB testing among PLHIV who are at continued high risk of 
exposure is limited to expert opinion and clinical experience. Our analysis identified 
characteristics of PLHIV that providers can use to inform the decision regarding annual, 
targeted testing for LTBI. Among those tested at least once since HIV diagnosis, PLHIV 
who had a positive LTBI test were more likely to be foreign-born, have lower educational 
attainment, or have a household income below the US federal poverty level. The Dutch study 
found African origin to be significantly associated with LTBI in their population.5 We 
recommend that providers periodically evaluate risk for exposure to and transmission of M. 
tuberculosis, particularly if individual patients develop new risk factors.
A challenge with LTBI testing using the tuberculin skin test (TST) is loss to follow-up, as 
two clinical encounters are required to administer and interpret a TST. Among patients 
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tested at least once in our study but without a documented result, 25.1% were reported as an 
unread TST. The increased use of IGRAs instead of the TST for LTBI testing in HIV care 
would result in higher test completion rates, as it involves only a single health care visit. 
Although prior testing data are not presented, the study by van Bentum et al. achieved LTBI 
testing results using an IGRA in 599 (80.7%) of 742 PLHIV during an 18-month study 
period.5 Only 19% of PLHIV in our study were tested by an IGRA over a 5-year study 
period; an additional 2.7% of PLHIV would potentially have an LTBI test result had they 
been tested by IGRA instead of TST.
Given the similarities in HIV and TB epidemiology between the United States and the 
Netherlands, the findings from the Dutch study contribute to the evidence supporting the 
recommendations for LTBI testing among PLHIV at diagnosis and annually, based on risk. 
As low-incidence settings seek to accelerate progress towards TB elimination, improving 
LTBI testing and treatment for PLHIV will be an essential element of any comprehensive 
strategy.
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